Intermediate‐Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance

[1]  Liying Zhang,et al.  Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. , 2016, The Journal of urology.

[2]  J. Hugosson,et al.  Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. , 2016, European urology.

[3]  Liying Zhang,et al.  Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. , 2016, The Journal of urology.

[4]  M. Cooperberg,et al.  Genomic Predictors of Outcome in Prostate Cancer. , 2015, European urology.

[5]  Mufaddal Mamawala,et al.  Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[7]  A. Evans,et al.  Active surveillance for the management of localized prostate cancer: Guideline recommendations. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[8]  M. Loda,et al.  Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.

[9]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[10]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[12]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[13]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Soloway,et al.  Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. , 2010, European urology.

[15]  H. G. van der Poel,et al.  Short‐term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study , 2010, BJU international.

[16]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[17]  B. Guillonneau,et al.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. , 2008, The Journal of urology.

[18]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[19]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[20]  Christopher J Kane,et al.  Prostate Cancer, Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  P. Maté Mate.  [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.

[22]  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.